AlphaRx To Present at 47th Annual ICAAC
Dr. Joseph Schwarz, Chief Scientist of AlphaRx is scheduled to present"Effective Treatment of Tuberculosis in Mice with NanoparticulatedStreptomycin." The presentation will elucidate that Streptomycin in theCompany's nanoparticulated delivery platform, demonstrated increased efficacyand is effectively a cure of model tuberculosis at a dosage 80% lower thanthat of free drug, provided 100% survival in experimental TB mice model andexhibited noticeable sustained release and targeting of the incorporated drug.
For more information on AlphaRx visit, www.Alpharx.com. For moreinformation on the ICAAC 47th annual meeting, scheduled for September 17-20,2007, visit www.icaac.org.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietarysite-specific nanoparticulate drug delivery systems to develop novelformulations of drugs that are insoluble or poorly soluble in water or haveyet to be administrable to the human body with an acceptable delivery method.The Company also discovers and develops novel, small-molecule drugs for thetreatment of inflammatory diseases and neurodegenerative diseases.
This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the companies.
SOURCE AlphaRx Inc.
You May Also Like